GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » PE Ratio without NRI

Embecta (Embecta) PE Ratio without NRI : 5.61 (As of Apr. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-04-26), Embecta's share price is $10.485. Embecta's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.87. Therefore, Embecta's PE Ratio without NRI for today is 5.61.

During the past 5 years, Embecta's highest PE Ratio without NRI was 18.94. The lowest was 3.96. And the median was 8.21.

Embecta's EPS without NRI for the three months ended in Dec. 2023 was $0.35. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.87.

As of today (2024-04-26), Embecta's share price is $10.485. Embecta's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.95. Therefore, Embecta's PE Ratio for today is 11.04.

During the past years, Embecta's highest PE Ratio was 26.67. The lowest was 3.96. And the median was 11.52.

Embecta's EPS (Diluted) for the three months ended in Dec. 2023 was $0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.95.

Embecta's EPS (Basic) for the three months ended in Dec. 2023 was $0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.96.


Embecta PE Ratio without NRI Historical Data

The historical data trend for Embecta's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta PE Ratio without NRI Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
PE Ratio without NRI
N/A N/A N/A 6.02 5.03

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 17.36 17.42 5.03 10.12

Competitive Comparison of Embecta's PE Ratio without NRI

For the Medical Instruments & Supplies subindustry, Embecta's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embecta's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Embecta's PE Ratio without NRI falls into.



Embecta PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Embecta's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=10.485/1.870
=5.61

Embecta's Share Price of today is $10.485.
Embecta's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Embecta  (NAS:EMBC) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Embecta PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Embecta's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (Embecta) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015